Jeanine Cook-Gerard from the Department of Nursing talks with John Maslowski, President and Chief Executive Officer of Fibrocell, about the rare genetic skin disease Recessive Dystrophic Epidermolysis Bullosa (RDEB). John describes Fibrocell’s main objective - to find a cure for RDEB and announces that the FDA is now allowing the second phase of this clinical trial in which Fibrocell will be enrolling six pediatric patients ages 7 and older.